H. Lundbeck AS Ordinary Shares - Class B
HLUN B: XCSE (DNK)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|.@& | LOCK|$B | LOCK|KTh?^t% |
No-Moat Lundbeck's Strategic Brands Drive Sales, but Loss of Exclusivity Weighs on Long-Term Outlook
Business Strategy and Outlook
Lundbeck's portfolio focuses on central nervous system drugs, including antidepressants, antipsychotics, and antiepileptic products. While incremental innovations and label expansions helped Lundbeck earn excess returns over the past several years, this occurred before many of Lundbeck’s patents expired. Since then, generic entry has created significant competition and pricing pressure for the firm.
